Enanta Pharmaceuticals (ENTA) Shares Outstanding (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Shares Outstanding (Entity) came in at $29.1 million in Q1 2026, up 35.95% YoY from $21.4 million in Q1 2025, and little changed on a QoQ basis from $29.0 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Shares Outstanding (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Shares Outstanding (Entity) data on file, last reported at $29.1 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 35.95% year-over-year to $29.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (up 35.95% YoY) and the FY2025 annual result came in at $21336.0, up 0.85% from the prior year.
- Shares Outstanding (Entity) was little changed at $29.1 million in Q1 2026, from $29.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $29.1 million in Q1 2026 to a low of $20603.0 in Q3 2022.
- A 5-year average of $17.1 million and a median of $21.1 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) rose 0.6% — and 2025, when it surged 36.03%.
- Tracing ENTA's Shares Outstanding (Entity) over 5 years: stood at $20.9 million in 2022, then grew by 1.3% to $21.2 million in 2023, then advanced by 0.84% to $21.3 million in 2024, then surged by 36.03% to $29.0 million in 2025, then gained by 0.14% to $29.1 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $29.1 million (Q1 2026), $29.0 million (Q4 2025), and $21336.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 29.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.04 Mn |
| Mar 31, 2026 | 29.04 Mn |
| Dec 31, 2025 | 28.75 Mn |
| Sep 30, 2025 | 21,336.00 |
| Jun 30, 2025 | 21.38 Mn |
| Mar 31, 2025 | 21.36 Mn |
| Dec 31, 2024 | 21.24 Mn |
| Sep 30, 2024 | 21,157.00 |
| Jun 30, 2024 | 21.18 Mn |
| Mar 31, 2024 | 21.17 Mn |
| Dec 31, 2023 | 21.09 Mn |
| Sep 30, 2023 | 20,969.00 |
| Jun 30, 2023 | 21.05 Mn |
| Mar 31, 2023 | 21.04 Mn |
| Dec 31, 2022 | 20.82 Mn |
| Sep 30, 2022 | 20,603.00 |
| Jun 30, 2022 | 20.71 Mn |
| Mar 31, 2022 | 20.55 Mn |
| Dec 31, 2021 | 20.39 Mn |
| Sep 30, 2021 | 20,171.00 |